Head-to-head: Potent hepatitis B antivirals compared
The drugs appear similarly effective in reducing risk of liver cancer, studies show
Tenofovir and entecavir appear to be equally effective in reducing risk of hepatocellular carcinoma (HCC) and all-cause mortality in people with hepatitis B over five years, a ‘real-world’ study suggests.
In the longest follow-up to date, more than 3000 patients with hepatitis B attending the Catholic University of Korea’s liver clinics were included in a retrospective analysis, with 1439 on tenofovir and 1583 taking entecavir.
